High Resolution Structures of Human TorsinA and TorsinAΔE302/303 in Complex with its Activator LULL1 as a Platform for Drug Design for Dystonia

Technology #18394

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Image Gallery
Crystal structure of the mutant TorsinA-LLUL1 complex.
Categories
Inventors
Professor Thomas Schwartz
Department of Biology, MIT
External Link (schwartzlab.mit.edu)
Fatma Demircioglu
Department of Biology, MIT
Brian Sosa-Alvarado
Department of Biology, MIT
Managed By
Jon Gilbert
MIT Technology Licensing Officer
Patent Protection

Crystal Structures of Human Torsin A and its Dystonia Mutant

Provisional Patent Application Filed

Crystal Structures of Human Torsin A and its Dystonia Mutant

Provisional Patent Application Filed

Applications

  • Treatment for Early-Onset and other forms of Dystonia

Problem Addressed

A single-chain antibody fragment, known as nanobody, has been developed to serve as a crystallization chaperone for the structural characterization of TorsinA. The crystal structures of TorsinA as well as the Dystonia mutant TorsinADE302/303, both in complex with the activator LULL1, have been determined. These structures may lead to the development of a drug that can rescue the weakened TorsinADE302/303-activator interaction, with high potential of providing a cure for early-onset primary Dystonia.

Technology

Early-onset, torsion dystonia (DYT1) is a genetic disease affecting an estimated 50,000 patients in the United Sates alone. It is an incurable and severely debilitating neuromuscular disease. A single glutamate deletion at position 302 or 303 of the protein TorsinA (TorsinADE302/303) is the primary cause of DYT1. TorsinA is an enzyme that resides in the endoplasmic reticulum of the cell, where it most likely functions in protein or membrane remodeling. TorsinA is activated by lamina-associated protein 1 (LAP1) and by luminal domain-like LAP1 (LULL1). The TorsinADE302/303 mutant weakens the binding of the activators LAP1/LULL1, which likely presents the molecular basis for the disease. If binding to the activator can be restored, for examples by a small molecule, this may represent the drug needed to cure the disease. Here, a single-chain antibody fragment, or nanobody, called VHH-BS2, which specifically binds TorsinA and LULL1 has been found. Using this nanobody as a crystallization chaperone, both TorsinA-LULL1-VHH-BS2 and mutant TorsinADE302/303-LULL1-VHH-BS2 complexes were crystallized and the structures solved at very high resolution (1.4 Å). The ability to stabilize a weak interaction such as the one between mutant TorsinA and LULL1 is extremely rare and immediately suggests the possibility to provide a structural basis for rational drug design for DYT1.

Advantages

Crystal structures of wild type and dystonia mutant TorsinA protein complexes with nanobody and associated LULL1 activating protein have been determined at the nearly atomic resolution of 1.4 Å. The structures have a resolution that can directly be used for computational drug design. The TorsinA structure has been pursued for 20 years and only the use of the specific nanobody finally enabled crystallization.